The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Open accessPublished version of a preprint
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein 1-5 show promise therapeutically and are being evaluated clinically 6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs 9. Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The T478K mutation in the RBD is unique to the Delta variant and falls within the epitope region of potent neutralizing monoclonal antibodies categorized as 'Class1' 17”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Although circulating antibodies derived from plasma cells wane over time, long-lived immune memory can persist in expanded clones of memory B cells7,20.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“As seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less effective against pseudotyped viruses carrying the E484K mutation7,12,29.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [23]
In the citing paper
“Residue S477 is close to the receptor binding site (Fig ED2) and part of the epitope recognized by the S2E12 and C102 neutralizing antibodies 17,18 .”
From Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (2021) · cites this paper as [17]
In the citing paper
“a potent Ab that can recognize both “up” and “down” SARS-CoV-2 RBD conformations [41].”
From Deep geometric representations for modeling effects of mutations on protein-protein binding affinity (2021) · cites this paper as [41]
In the citing paper
“Importantly, our spike did not contain R346K, which has been observed at relatively low frequency (<10%) within the Omicron lineage, but which is known to mediate escape from class 3 neutralizing monoclonal antibodies such as AZD1061/cilgavimab (Barnes et al., 2020; Dong et al., 2021; Greaney et al., 2021b).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Cited by
Sorted by citations
Items 201–300 of 1,004
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Hanke, L., Das, H., Sheward, D. J., Vidakovics, L. P., Urgard, E., Moliner-Morro, A., Kim, C., Karl, V., Pankow, A. P., Smith, N. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27610-z · Cited by 80
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines
Liang, C.-Y., Raju, S., Liu, Z., Li, Y., Arunkumar, G. A., Case, J. B., Scheaffer, S. M., Zost, S. J., Acreman, C. M., Gagné, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07539-1 · Cited by 92
Batty, C. J., Heise, M. T., Bachelder, E. M., & Ainslie, K. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.006 · Cited by 86
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 78
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Hagemann, K., Riecken, K., Jung, J. M., Hildebrandt, H., Menzel, S., Bunders, M. J., Fehse, B., Koch‐Nolte, F., Heinrich, F., Peine, S., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149470 · Cited by 76
Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike
Brun, J., Vasiljević, S., Gangadharan, B., Hensen, M., Chandran, A. V., Hill, M. L., Kiappes, J. L., Dwek, R. A., Alonzi, D. S., Struwe, W. B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00058 · Cited by 92
Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
Rujas, E., Kucharska, I., Tan, Y. Z., Benlekbir, S., Cui, H., Zhao, T., Wasney, G. A., Budylowski, P., Guvenc, F., Newton, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23825-2 · Cited by 75
Sun, S., Cai, Y., Song, T., Yang, P., Cheng, L., Xu, H., Sun, J., Meng, C., Lin, Y., Huang, H., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00531-8 · Cited by 78
Liu, H., Wei, P., Kappler, J. W., Marrack, P., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825256 · Cited by 84
Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 77
Wang, C. Y., Hwang, K.-P., Kuo, H.-K., Peng, W.-J., Shen, Y.-H., Kuo, B.-S., Huang, J.-H., Liu, H., Ho, Y.-H., Lin, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157707 · Cited by 82
Self-citationSARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
Reincke, S. M., Yuan, M., Kornau, H., Corman, V. M., van Hoof, S., Sánchez-Sendín, E., Ramberger, M., Yu, W., Hua, Y., Tien, H. J., et al. (2022) · Science · doi:10.1126/science.abm5835 · Cited by 75
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“These classes of mAbs was found to trigger S rearrangement to the post-fusion state, likely due to conformational selection for open RBDs, and promotemembrane fusion (Lempp et al., 2021).”
InfluentialShastri, J. S., Parikh, S., Aggarwal, V., Agrawal, S. R., Chatterjee, N., Shah, R. J., Devi, P., Mehta, P., & Pandey, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.737007 · Cited by 78
Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 81
Tao, K., Tzou, P. L., Pond, S. L. K., Ioannidis, J. P. A., & Shafer, R. W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00926-22 · Cited by 84
He, P., Liu, B., Gao, X., Yan, Q., Pei, R., Sun, J., Chen, Q., Hou, R., Li, Z., Zhang, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01235-4 · Cited by 76
Bowen, J. E., Park, Y., Stewart, C., Brown, J. T., Sharkey, W. K., Walls, A. C., Joshi, A., Sprouse, K. R., McCallum, M., Tortorici, M. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.adf1421 · Cited by 81
Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
Kaku, C. I., Champney, E. R., Normark, J., García, M., Johnson, C. E., Ahlm, C., Christ, W., Sakharkar, M., Ackerman, M. E., Klingström, J., et al. (2022) · Science · doi:10.1126/science.abn2688 · Cited by 75
Bauer, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.061 · Cited by 74
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
Asarnow, D. E., Wang, B., Lee, W.-H. S., Hu, Y., Huang, C.-W., Faust, B., Ng, P. M. L., Ngoh, E. Z. X., Bohn, M., Bulkley, D. P., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.033 · Cited by 75
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Norman, A. R., Franck, C., Christie, M., Hawkins, P. M. E., Patel, K., Ashhurst, A. S., Aggarwal, A., Low, J. K. K., Siddiquee, R., Ashley, C. L., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01708 · Cited by 76
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
Mast, F. D., Fridy, P. C., Ketaren, N. E., Wang, J., Jacobs, E. Y., Olivier, J. P., Sanyal, T., Molloy, K. R., Schmidt, F., Rutkowska, M., et al. (2021) · eLife · doi:10.7554/elife.73027 · Cited by 69
Gittelman, R. M., Lavezzo, E., Snyder, T. M., Zahid, H. J., Carty, C. L., Elyanow, R., Dalai, S. C., Kirsch, I. R., Baldo, L., Manuto, L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151849 · Cited by 78
A broad and potent neutralization epitope in SARS-related coronaviruses
Yuan, M., Zhu, X., He, W., Zhou, P.-P., Kaku, C. I., Capozzola, T., Zhu, C. Y., Yu, X., Liu, H., Yu, W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205784119 · Cited by 77
Wu, N. C., Yuan, M., Bangaru, S., Huang, D., Zhu, X., Lee, C.-C. D., Turner, H. L., Peng, L., Yang, L., Burton, D. R., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009089 · Cited by 71
Yan, R., Wang, R., Ju, B., Yu, J., Zhang, Y., Liu, N., Wang, J., Zhang, Q., Chen, P., Zhou, B., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00487-9 · Cited by 72
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
Huang, K.-Y. A., Tan, T. K., Chen, T.-H., Huang, C., Harvey, R., Hussain, S., Chen, C., Harding, A. C., Gilbert‐Jaramillo, J., Liu, X., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009352 · Cited by 67
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Witte, L., Baharani, V. A., Schmidt, F., Wang, Z., Cho, A., Raspe, R., Guzmán-Cardozo, C., Muecksch, F., Canis, M., Park, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35927-0 · Cited by 68
Self-citationVerkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00139 · Cited by 62
Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167155 · Cited by 72
Mortari, E. P., Russo, C., Vinci, M. R., Terreri, S., Salinas, A. F., Piccioni, L., Alteri, C., Colagrossi, L., Coltella, L., Ranno, S., et al. (2021) · Cells · doi:10.3390/cells10102541 · Cited by 72
Cerutti, G., Guo, Y., Wang, P., Nair, M. S., Wang, M., Huang, Y., Yu, J., Liu, L., Katsamba, P. S., Bahna, F. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109928 · Cited by 63
Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71
Planchais, C., Fernández, I., Bruel, T., de Melo, G. D., Prot, M., Beretta, M., Guardado‐Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backović, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220638 · Cited by 75
A rapid cell-free expression and screening platform for antibody discovery
Hunt, A. C., Vögeli, B., Hassan, A. O., Guerrero, L., Kightlinger, W., Yoesep, D. J., Krüger, A., DeWinter, M. A., Diamond, M., Karim, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38965-w · Cited by 80
Chakraborty, C., Bhattacharya, M., Sharma, A. R., & Mallik, B. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.254 · Cited by 74
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
Zhang, L., Cao, L., Gao, X., Zheng, B., Deng, Y., Li, J., Feng, R., Bian, Q., Guo, X., Wang, N., et al. (2021) · National Science Review · doi:10.1093/nsr/nwab053 · Cited by 69
De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model
He, H., He, B., Guan, L., Zhao, Y., Jiang, F., Chen, G., Zhu, Q.-G., Chen, C. Y., Li, T., & Yao, J. (2024) · Nature Communications · doi:10.1038/s41467-024-50903-y · Cited by 78
The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein
Dokainish, H. M., Re, S., Mori, T., Kobayashi, C., Jung, J., & Sugita, Y. (2022) · eLife · doi:10.7554/elife.75720 · Cited by 70
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesPreprint
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.03.471045 · Cited by 69
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100527 · Cited by 80
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lü, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00985-w · Cited by 74
Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant
Ma, W., Yang, J., Fu, H., Su, C., Yu, C., Wang, Q., de Vasconcelos, A. T. R., Bazykin, G. A., Bào, Y., & Li, M. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.001 · Cited by 59
Finkelstein, M. T., Mermelstein, A. G., Miller, E. P., Seth, P. C., Stancofski, E.-S. D., & Fera, D. (2021) · Viruses · doi:10.3390/v13010134 · Cited by 63
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64
Yang, T., Yu, P., Chang, Y., Kuo, C., Khoo, K., & Hsu, S. D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101238 · Cited by 63
Mannar, D., Saville, J. W., Sun, Z., Zhu, X. Q., Martí, M. M., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Sobolewski, M. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32262-8 · Cited by 65
Wang, Z., Zhou, P., Muecksch, F., Cho, A., Tanfous, T. B., Canis, M., Witte, L., Johnson, B., Raspe, R., Schmidt, F., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221006 · Cited by 61
Self-citationPredicting the antigenic evolution of SARS-COV-2 with deep learning
Han, W., Chen, N., Xu, X., Sahil, A., Zhou, J., Li, Z., Zhong, H., Gao, E., Zhang, R., Wang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39199-6 · Cited by 66
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
Hills, R. A., Tan, T. K., Cohen, A. A., Keeffe, J. R., Keeble, A. H., Gnanapragasam, P. N. P., Storm, K. N., Rorick, A. V., West, A. P., Hill, M. L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01655-9 · Cited by 82
Self-citationB.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies
Zhan, Y., Yin, H. Y., & Yin, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66881 · Cited by 68
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Rapp, M., Guo, Y., Reddem, E. R., Yu, J., Liu, L., Wang, P., Cerutti, G., Katsamba, P. S., Bimela, J. S., Bahna, F. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108950 · Cited by 59
Liu, H., Yuan, M., Huang, D., Bangaru, S., Zhao, F., Lee, C.-C. D., Peng, L., Barman, S., Zhu, X., Nemazee, D. A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 58
Verkhivker, G. M., & Paola, L. D. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00395 · Cited by 55
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Wheatley, A. K., Pymm, P., Esterbauer, R., Dietrich, M. H., Lee, W. S., Drew, D. R., Kelly, H. G., Chan, L., Mordant, F. L., Black, K. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109822 · Cited by 62
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J. E., Logue, J. K., Corti, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010248 · Cited by 58
Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 67
Chen, W., Wei, J., Kundu, R. T., Adhikari, R., Liu, Z., Lee, J., Versteeg, L., Poveda, C., Keegan, B. P., Villar, M. J., et al. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129893 · Cited by 62
Dussupt, V., Sankhala, R. S., Mendez-Rivera, L., Townsley, S., Schmidt, F., Wieczorek, L., Lal, K. G., Donofrio, G. C., Tran, U., Jackson, N. D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01068-z · Cited by 59
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Liu, C., Zhou, D.-M., Nutalai, R., Duyvesteyn, H., Tuekprakhon, A., Ginn, H., Dejnirattisai, W., Supasa, P., Mentzer, A., Wang, B.-B., et al. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.11.013 · Cited by 65
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
Claireaux, M. A. F., Caniels, T. G., de Gast, M., Han, J., Guerra, D., Kerster, G., van Schaik, B. D. C., Jongejan, A., Schriek, A. I., Grobben, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32232-0 · Cited by 64
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New YorkPreprint
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Lonardo, S. S. D., Hughes, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.14.431043 · Cited by 74
Self-citationA Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
Niu, L., Wittrock, K. N., Clabaugh, G. C., Srivastava, V., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647934 · Cited by 62
Cerutti, G., Rapp, M., Guo, Y., Bahna, F. A., Bimela, J. S., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., et al. (2021) · Structure · doi:10.1016/j.str.2021.05.014 · Cited by 59
Structures of Omicron spike complexes and implications for neutralizing antibody development
Guo, H., Gao, Y., Li, T., Li, T., Lu, Y., Zheng, L., Liu, Y., Yang, T., Luo, F., Song, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110770 · Cited by 61
Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures
Taeschler, P., Cervia, C., Zurbuchen, Y., Hasler, S., Pou, C., Tan, Z., Adamo, S., Raeber, M. E., Bächli, E., Rudiger, A., et al. (2022) · Allergy · doi:10.1111/all.15302 · Cited by 64
He, W., Musharrafieh, R. G., Song, G., Dueker, K., Tse, L. V., Martinez, D. R., Schäfer, A., Callaghan, S., Yong, P., Beutler, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01222-1 · Cited by 58
The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
Moulana, A., Dupic, T., Phillips, A. M., Chang, J., Roffler, A. A., Greaney, A. J., Starr, T. N., Bloom, J. D., & Desai, M. M. (2023) · eLife · doi:10.7554/elife.83442 · Cited by 62
Zhang, Z., Zeng, E., Zhang, L., Wang, W., Jin, Y., Sun, J., Huang, S., Yin, W., Dai, J., Zhuang, Z., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00302-0 · Cited by 60
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 62
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile
Alkhatib, M., Salpini, R., Carioti, L., Ambrosio, F. A., D’Anna, S., Duca, L., Costa, G., Bellocchi, M. C., Piermatteo, L., Artese, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02732-21 · Cited by 64
Onodera, T., Kita, S., Adachi, Y., Moriyama, S., Sato, A., Nomura, T., Sakakibara, S., Inoue, T., Tadokoro, T., Anraku, Y., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.025 · Cited by 61
Klinakis, A., Cournia, Z., & Rampias, T. N. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.004 · Cited by 59
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 58
Evolution of antibody immunity following Omicron BA.1 breakthrough infection
Kaku, C. I., Starr, T. N., Zhou, P.-P., Dugan, H. L., Khalifé, P., Song, G., Champney, E. R., Mielcarz, D. W., Geoghegan, J. C., Burton, D. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38345-4 · Cited by 70
Development and application of therapeutic antibodies against COVID-19
Lin, N., Abagna, H. B., Jiang, Q., Liu, S., & Huang, J. H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59149 · Cited by 61
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
Dickey, T. H., Tang, W. K., Butler, B., Ouahes, T., Orr-Gonzalez, S., Salinas, N. D., Lambert, L., & Tolia, N. H. (2022) · Science Advances · doi:10.1126/sciadv.abq8276 · Cited by 59
Fan, C., Cohen, A. A., Park, M., Hung, A. F.-H., Keeffe, J. R., Gnanapragasam, P. N. P., Lee, Y. E., Gao, H., Kakutani, L. M., Wu, Z., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.019 · Cited by 56
Self-citationFeldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 60
Ishii, H., Nomura, T., Yamamoto, H., Nishizawa, M., Hau, T. T. T., Harada, S., Seki, S., Nakamura‐Hoshi, M., Okazaki, M., Daigen, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100520 · Cited by 59
Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells
Chen, J., Fan, J., Chen, Z., Zhang, M., Peng, H., Jian, L., Ding, L., Liu, M., Zhao, C., Zhao, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111011118 · Cited by 59
Akerman, A., Milogiannakis, V., Jean, T., Esneau, C., Silva, M. R., Ison, T., Fichter, C., Lopez, J. A., Chandra, D., Naing, Z., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104545 · Cited by 56
Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Serra, M. G., Kreer, C., et al. (2021) · Viruses · doi:10.3390/v13081498 · Cited by 53
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 55
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprintingPreprint
Yisimayi, A., Song, W., Wang, J., Jian, F., Yu, Y., Chen, X., Xu, Y., Yang, S., Niu, X., Xiao, T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.01.538516 · Cited by 56
Fédry, J., Hurdiss, D. L., Wang, C., Li, W., Obal, G., Drulyte, I., Du, W., Howes, S. C., van Kuppeveld, F. J. M., Förster, F. G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf5632 · Cited by 54
Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor
Taka, E., Yilmaz, S. Z., Gölcük, M., Kılınç, C., Aktas, U., Yıldız, A., & Gür, M. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c02048 · Cited by 54
Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis
Kim, S., & Lee, J. (2022) · BioChip Journal · doi:10.1007/s13206-022-00078-9 · Cited by 56
Advances in developing ACE2 derivatives against SARS-CoV-2
Zhang, H., Lv, P., Jiang, J., Liu, Y., Yan, R., Shu, S., Hu, B., Xiao, H., Cai, K., Yuan, S., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00011-3 · Cited by 57
Structure and inhibition of SARS-CoV-2 spike refolding in membranes
Grunst, M. W., Qin, Z., Dodero‐Rojas, E., Ding, S., Prévost, J., Chen, Y., Hu, Y., Pazgier, M., Wu, S., Xie, X., et al. (2024) · Science · doi:10.1126/science.adn5658 · Cited by 61
Jian, F., Wec, A. Z., Feng, L., Yu, Y., Wang, L., Wang, P., Yu, L., Wang, J., Hou, J., Berrueta, D. M., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02030-7 · Cited by 57
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Ma, M. T., Badeti, S., Chen, C.-H., Kim, J., Choudhary, A. K., Honnen, B., Reichman, C., Calianese, D. C., Pinter, A., Jiang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652223 · Cited by 54
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
Dacon, C., Peng, L., Lin, T.-H., Tucker, C., Lee, C.-C. D., Cong, Y., Wang, L., Purser, L., Cooper, A. J. R., Williams, J. K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.010 · Cited by 54
Zupancic, J. M., Desai, A. A., Schardt, J. S., Pornnoppadol, G., Makowski, E. K., Smith, M. D., Kennedy, A. A., Barbosa, M. G. D. M., Cascalho, M., Lanigan, T. M., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.019 · Cited by 53
Mor, M., Werbner, M., Alter, J., Safra, M., Chomsky, E., Lee, J. C., Hada-Neeman, S., Polonsky, K., Nowell, C. J., Clark, A. E., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009165 · Cited by 52
Metadata
- Authors
- Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Institute for Research in Biomedicine (CH)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2020-10-12
- Volume
- 588
- Issue
- 7839
- Pages
- 682-687
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8092461
- OpenAlex
- W3092403777
- Cited by
- 1,599
- References
- 70
- Citations by year
- 2026: 94 · 2025: 121 · 2024: 181 · 2023: 267 · 2022: 448 · 2021: 440 · 2020: 35
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-02)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy (P41GM103393, DE-AC02-)
- Burroughs Wellcome Fund
- George Mason University
- California Institute of Technology
- Wellcome Trust
- National Institutes of Health (AI138938, P01 AI138938-S1, AI150464)
- Office of Science (P41GM103393, DE-AC02)
- Beckman Institute, California Institute of Technology
- National Institute of General Medical Sciences (AI150464, P41GM103393)
- National Institute of Allergy and Infectious Diseases (P50AI150464, F30AI147579, P01AI138938)
- Basic Energy Sciences (DE-AC02, P41GM103393)
- Biological and Environmental Research (P41 GM103393)
- SLAC National Accelerator Laboratory (P41GM103393)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein receptor-binding domain, antibody-antigen complex structure, ACE2 receptor, epitope mapping, N-glycans, somatic hypermutation, antibody escape, avidity, antibody combination therapy, spike trimer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
